Skip to content
The Policy Vault
Methodology
Why
Contact
Coverage
/
Cigna
/
Tibsovo (ivosidenib tablets)
/
Bone Cancer (chondrosarcoma)
← Back
Tibsovo (ivosidenib tablets) — Cigna
Bone Cancer (chondrosarcoma)
Initial criteria
Patient has chondrosarcoma
Patient has isocitrate dehydrogenase-1 (IDH1) mutation-positive disease
Approval duration
1 year